Systemic treatment options with proven efficacy for the treatment of metastatic uveal melanoma are limited. In this study, we aimed to evaluate the efficacy of nivolumab in metastatic uveal melanoma patients. In our multi-center study, the files of patients who received nivolumab treatment with a diagnosis of metastatic uveal melanoma were retrospectively reviewed and their information was recorded. Seventeen patients were enrolledand 16 patients were evaluable for efficacy. The objective response rate (ORR) was 18% including one confirmed complete response and two confirmed partial responses. The median progression-free survival (PFS) was 5.8 months (95% CI, 0.03-11.57 months), and the median overall survival (OS) was 10.5 months (95% CI, 3.87-14.14 months). Significant longer OS and PFS were observed in patients with the performance status of the Eastern Cooperative Oncology Group (ECOG-PS) 0. Although significant longer OS was detected in patients with low median lactate dehydrogenase (LDH) levels, no significant difference was found in PFS. Grade 1 and 2 fatigue and decreased appetite were the most common side effects associated with treatment (17%); grade 3 and 4 side effects were not observed. Immunotherapy is also emerging as a treatment option among the limited number of treatment options in metastatic uveal melanoma (mUM), but its efficacy needs to be demonstrated with prospective studies involving a larger number of patients.

中文翻译：

---

纳武单抗治疗转移性葡萄膜黑色素瘤：一项多中心回顾性研究。

对于转移性葡萄膜黑色素瘤的治疗已证实有效的全身治疗方案是有限的。在本研究中，我们旨在评估纳武单抗对转移性葡萄膜黑色素瘤患者的疗效。在我们的多中心研究中，对接受纳武单抗治疗并诊断为转移性葡萄膜黑色素瘤的患者的档案进行了回顾性审查并记录了他们的信息。招募了 17 名患者，其中 16 名患者可进行疗效评估。客观缓解率 (ORR) 为 18%，其中 1 例确认完全缓解，2 例确认部分缓解。中位无进展生存期 (PFS) 为 5.8 个月（95% CI，0.03-11.57 个月），中位总生存期 (OS) 为 10.5 个月（95% CI，3.87-14.14 个月）。在东部肿瘤合作组 (ECOG-PS) 0 表现状态的患者中观察到 OS 和 PFS 显着延长。尽管在中位乳酸脱氢酶 (LDH) 水平较低的患者中检测到 OS 显着延长，但在无进展生存期。1 级和 2 级疲劳和食欲下降是与治疗相关的最常见副作用 (17%)；未观察到 3 级和 4 级副作用。免疫疗法也正在成为转移性葡萄膜黑色素瘤 (mUM) 有限治疗方案中的一种治疗方案，但其疗效需要通过涉及更多患者的前瞻性研究来证明。